Corporate Misconduct Accountability Project
Fresenius Medical Care Holdings, Inc. · Multidistrict Litigation / Class Action
Fresenius GranuFlo: Dialysis Product Linked to Cardiac Arrest
Fresenius Medical Care faced multidistrict litigation alleging its GranuFlo dialysis product caused cardiopulmonary arrests. Court documents reveal delayed warnings and procedural barriers blocking injured patients and insurers from timely relief.
CRITICAL SEVERITY
TL;DR
Fresenius Medical Care manufactured GranuFlo, an acid concentrate used in hemodialysis. In March 2012, the company issued a public memo warning that GranuFlo could lead to cardiopulmonary arrest in certain patients. This announcement triggered hundreds of wrongful death and personal injury lawsuits consolidated into multidistrict litigation. Third-party healthcare payors, represented by MSP Recovery, claimed they suffered financial losses covering treatments for injuries allegedly caused by the defective product. The First Circuit Court of Appeals ruled that MSP’s claims were filed too late under statute of limitations rules, effectively barring recovery on procedural grounds rather than addressing the substance of the safety allegations.
Corporate legal strategies can shield companies from accountability even when serious patient harm is alleged.
2012
Year Fresenius issued public warning about GranuFlo cardiac risks
2013
Berzas class action filed alleging product defects and unfair trade practices
2018
MSP Recovery filed suit, six years after claims first accrued
9
Named plaintiffs in original Berzas class action complaint
The Allegations: A Breakdown
Core Allegations
What they did · 8 points
| 01 | Fresenius manufactured and distributed GranuFlo, an acid concentrate used in hemodialysis treatments that the company later admitted could lead to cardiopulmonary arrest in certain patients. | high |
| 02 | On March 29, 2012, Fresenius issued a public memorandum explaining GranuFlo’s cardiac risks and advising doctors to exercise their best clinical judgment when prescribing and administering treatments. | high |
| 03 | This 2012 announcement triggered a stream of wrongful death and personal injury lawsuits against Fresenius, all consolidated into multidistrict litigation in Massachusetts. | high |
| 04 | Plaintiffs in the Berzas class action alleged that GranuFlo and related product NaturaLyte were defective and that Fresenius engaged in deceptive and unfair trade practices in marketing and distributing them. | high |
| 05 | Healthcare payors claimed they paid for medical care to treat injuries sustained as a result of the defective GranuFlo products during hemodialysis. | medium |
| 06 | MSP Recovery asserted claims for negligence, product liability, and design defect under Massachusetts, New York, and Connecticut law on behalf of Medicare and Medicaid payors. | medium |
| 07 | All parties agreed that MSP’s claims accrued on March 29, 2012, the day Fresenius sent its public letter alerting medical providers to GranuFlo’s issues. | medium |
| 08 | MSP filed its complaint in September 2018, six years after the claims first accrued, which would normally render the suit untimely under all relevant statutes of limitations. | medium |
Exploiting Delay
Procedural warfare over substance · 8 points
| 01 | MSP Recovery argued that an earlier class action filed in 2013 tolled the statute of limitations through 2019 under American Pipe doctrine, allowing its 2018 complaint to proceed. | medium |
| 02 | Fresenius responded that tolling ended by June 2014 when Berzas plaintiffs filed Short Form Complaints and abandoned class allegations, making MSP’s 2018 suit untimely. | medium |
| 03 | The district court agreed with Fresenius and dismissed MSP’s case on statute of limitations grounds, never reaching the substance of the product safety allegations. | high |
| 04 | The First Circuit Court of Appeals affirmed dismissal, holding that MSP waited too long to file after the Berzas plaintiffs abandoned their class claims in 2014. | high |
| 05 | In 2014, five of nine original Berzas plaintiffs filed Short Form Complaints identifying only themselves and their next of kin as represented parties, with no reference to class claims. | medium |
| 06 | The other four Berzas plaintiffs filed stipulations of dismissal in June 2014, further ending any active pursuit of class certification. | medium |
| 07 | At an April 2015 conference, MDL plaintiffs’ counsel stated they were not planning to move for class certification and that cases were filed largely for equitable tolling purposes. | high |
| 08 | The Berzas plaintiffs took no action to move their claims forward over nearly five years, even as the MDL proceeding was reassigned to a different district court judge. | medium |
Regulatory Failures
Oversight gaps and agency inaction · 4 points
| 01 | The court record reveals that public warning of serious cardiac risks came from the corporation itself only after internal documents came to light in litigation, suggesting delayed regulatory action. | high |
| 02 | The case exemplifies structural challenges where regulatory bodies lack resources, enforcement muscle, or independence to quickly address corporate missteps. | medium |
| 03 | GranuFlo remained in widespread clinical use until lawsuits forced the company’s hand, indicating minimal post-market surveillance and enforcement. | high |
| 04 | The public relied on litigation after harm had already been done to unearth the truth about product risks, rather than proactive regulatory intervention. | high |
Profit Over People
Corporate calculations and patient risk · 5 points
| 01 | The question from lawsuits is whether Fresenius weighed the cost of comprehensive product warnings against potential lawsuit costs or reputational harm. | high |
| 02 | If Fresenius had acted sooner by withdrawing, redesigning, or issuing clearer warnings, lives might have been saved and financial losses spared. | high |
| 03 | The timing of lawsuits piling up after the 2012 memo suggests many felt Fresenius’s acknowledgment came too late to protect certain patients. | high |
| 04 | Corporations confronted with life-threatening product flaws face a choice between proactively addressing issues at possible expense to revenue or maintaining business as usual until external pressure forces action. | medium |
| 05 | The legal claims point toward Fresenius maintaining business as usual, with medical providers and insurers effectively kept in the dark while the company pursued ongoing sales. | high |
Economic Fallout
Shifting costs to the public · 6 points
| 01 | MSP Recovery asserted that healthcare payors, including Medicare and Medicaid payers, ultimately bore expenses that should never have arisen if Fresenius had properly safeguarded the product. | high |
| 02 | Wrongful death suits underscore that when systems fail, the cost of tragedy and grief borne by patients and their families is incalculable. | high |
| 03 | Taxpayer-funded healthcare programs like Medicare and Medicaid can bear the brunt of catastrophic medical events tied to corporate negligence. | high |
| 04 | When major healthcare payors face massive unexpected expenses, they recoup losses by charging more for premiums or cutting coverage, passing costs to customers. | medium |
| 05 | Insurance premiums for families, individuals, and employers offering health benefits could rise when third-party payors absorb sudden GranuFlo-related expenses. | medium |
| 06 | Public sector insurance programs might cover acute medical interventions for cardiopulmonary arrest stemming from a faulty device, meaning taxpayer dollars fill the gap when corporate accountability is delayed in court. | high |
Public Health and Safety
Vulnerable patients at risk · 5 points
| 01 | Dialysis recipients tend to be among the most vulnerable people in the healthcare system, often with underlying conditions making them highly susceptible to complications. | high |
| 02 | If claims are correct that Fresenius’s warning came late and was not robust enough, large populations could have been put in danger over an extended period. | high |
| 03 | A single defective or misused medical product can place enormous strain on local health infrastructures, especially in communities with limited access to alternative dialysis products or specialized kidney care centers. | medium |
| 04 | When powerful corporations fail to act responsibly, people in marginalized communities suffer disproportionately from both health impacts and economic consequences. | high |
| 05 | Distrust of healthcare providers or corporate manufacturers can fracture community relationships, potentially causing individuals to delay medical treatments out of fear. | medium |
Community Impact
Local lives disrupted · 6 points
| 01 | For families dealing with chronic kidney disease, dialysis is a lifeline, and in many regions Fresenius is a major or even the only provider of dialysis equipment and supplies. | high |
| 02 | When allegations like the GranuFlo controversy emerge, local communities feel the impact through potential patient harm and a general climate of distrust in healthcare offerings. | medium |
| 03 | The multidistrict litigation references numerous individual suits, each presumably tied to someone’s experience of heartbreak, expense, or loss. | medium |
| 04 | Should major concerns about a product’s safety escalate, some communities might face clinic closures or reorganizations, forcing patients to travel further for dialysis and disrupting daily life. | medium |
| 05 | Large-scale controversies erode social cohesion, and lack of transparency can worsen cynicism toward both the corporate world and public institutions seen as unable to regulate effectively. | medium |
| 06 | When a product as essential as a dialysis solution is implicated in wrongdoing, the impact on local lives is a fundamental violation of the trust people place in medical professionals and life-sustaining products. | high |
Worker Exploitation
Labor pressures and moral injury · 5 points
| 01 | Workers are often among those who first notice safety issues or product flaws, and whistleblower statements can be pivotal in exposing misconduct. | medium |
| 02 | When a corporation is under pressure to protect profit margins and suspects a product might be defective, internal labor issues can intensify. | medium |
| 03 | Companies may clamp down on employees, enforce tighter nondisclosure agreements, or discipline those who speak up about safety concerns. | medium |
| 04 | Given the scale of Fresenius’s operations in dialysis care, thousands of healthcare workers, technicians, and support staff are in direct or indirect employment. | low |
| 05 | If a product defect like GranuFlo leads to repeated patient crises, staff can experience stress, burnout, or moral injury knowing they might be administering a product flagged as unsafe. | high |
The PR Machine
Spin through silence and delay · 5 points
| 01 | Fresenius’s 2012 memorandum to healthcare providers acknowledged GranuFlo risks only after serious lawsuits were already looming, suggesting corporate PR tactics included information minimization. | high |
| 02 | Silence can be a powerful marketing tool, especially if acknowledging risk too early would damage sales or brand reputation. | medium |
| 03 | Large healthcare corporations often channel resources into lobbying to shape laws governing product approvals, liability standards, and regulatory oversight. | medium |
| 04 | By influencing legislation, corporations may create more lenient thresholds for proving consumer harm, thereby insulating themselves from accountability. | medium |
| 05 | When the official corporate narrative diverges sharply from lived experiences of patients or families, cynicism about corporate ethics grows. | medium |
Wealth Disparity
Power imbalance in litigation · 5 points
| 01 | Large-scale litigation reveals the imbalance in power and resources between multinational corporations and injured plaintiffs. | medium |
| 02 | Fresenius stands as a major global entity in renal care with significant market share, while plaintiffs find themselves in David versus Goliath scenarios burdened by legal fees and health complications. | medium |
| 03 | Even well-organized institutional plaintiffs like third-party payors face uphill battles when confronting the resources of a corporate titan in protracted litigation. | medium |
| 04 | If Fresenius evaded timely accountability for GranuFlo, then individuals who suffered medical complications or lost family members effectively subsidized the corporation’s profits. | high |
| 05 | Wealth inequality intensifies when corporations can pass financial, health, and social burdens of risky products to communities while high-level executives reap rewards. | high |
Corporate Accountability Failures
Justice deferred is justice denied · 6 points
| 01 | The appellate court’s rejection of MSP’s lawsuit rested on the timing of filing, not on any assessment that the underlying safety claims lacked substance. | high |
| 02 | The broader pattern involves penalties too small to deter the largest corporations, and many class actions end in settlements that barely dent profit margins of multinational entities. | medium |
| 03 | Court proceedings are typically reactive, kicking into gear once an individual files suit, while regulatory agencies meant to be proactive often lack agility and clout. | medium |
| 04 | Delays in sounding the alarm about GranuFlo’s dangers highlight how agencies often lack enforcement mechanisms, and corporations learn they can push the envelope with confidence. | high |
| 05 | Large-scale litigation can devolve into battles over legal technicalities rather than the substance of alleged misconduct, obscuring truth and blocking restitution for everyday people. | high |
| 06 | The intricate focus on American Pipe tolling and procedural timelines exemplifies how the legal system can appear designed to favor corporate defendants over injured patients and families. | high |
The Bottom Line
Systemic failure and unanswered questions · 7 points
| 01 | The lawsuit against Fresenius Medical Care over GranuFlo presents a microcosm of systemic challenges in American healthcare and the global economy. | medium |
| 02 | The appellate court decision addressed whether MSP Recovery’s claims were timely filed, a seemingly small question overshadowed by bigger themes of delayed warnings and profit-driven corporate culture. | high |
| 03 | By the time the final gavel fell, the public was left with more questions than answers about Fresenius’s internal decision-making and whether the company prioritized profits over transparency. | high |
| 04 | Underlying allegations remain that GranuFlo may have placed countless patients at grave risk and that corporate impetus to protect profits took precedence over immediate transparency. | high |
| 05 | This story is an urgent reminder of the dangers embedded in a system that treats vital healthcare technologies as profit-maximizing commodities. | high |
| 06 | When accountability arrives only after procedural wrestling in court, communities pay the price in lost lives, economic dislocation, and shattered trust. | high |
| 07 | The real question is whether the legal system can effectively address corporate behavior that endangers public health or whether technical defenses will continue to overshadow core accountability. | high |
Timeline of Events
March 29, 2012
Fresenius issues public memorandum warning that GranuFlo could lead to cardiopulmonary arrest in certain patients.
March 21, 2013
Berzas v. Fresenius class action filed in Eastern District of Louisiana alleging product defects and unfair trade practices.
February 13, 2014
Parties enter revised case management order directing plaintiffs to file Master Complaint and Short Form Complaints.
March 18, 2014
Five of nine Berzas plaintiffs file Short Form Complaints identifying only themselves and next of kin, with no class allegations.
June 27, 2014
Remaining four Berzas plaintiffs file stipulations of dismissal, effectively ending active class certification pursuit.
April 10, 2015
MDL plaintiffs’ counsel states they are not planning to move for class certification, citing equitable tolling purposes only.
2016
GranuFlo MDL parties report reaching private global settlement in principle to resolve vast majority of individual claims.
September 6, 2018
MSP Recovery files complaint, six years after claims first accrued in 2012.
April 30, 2019
Berzas action is finally closed after district court grants assented-to motion to sever remaining plaintiffs.
2023
District Court for District of Massachusetts denies MSP’s bid for American Pipe tolling and grants Fresenius’s motion to dismiss.
March 17, 2025
First Circuit Court of Appeals affirms dismissal, holding MSP waited too long after Berzas plaintiffs abandoned class claims in 2014.
Direct Quotes from the Legal Record
QUOTE 1
Cardiac arrest risk acknowledged
allegations
“On March 29, 2012, Fresenius issued a public memorandum explaining that GranuFlo could lead to cardiopulmonary arrest in certain patients and advising doctors to exercise their best clinical judgment when prescribing and administering treatments.”
💡 This admission triggered hundreds of wrongful death and injury lawsuits, revealing serious product risks.
QUOTE 2
Stream of wrongful death suits
allegations
“This announcement triggered a stream of wrongful death and personal injury lawsuits against Fresenius.”
💡 The scale of litigation demonstrates widespread harm and corporate accountability failures.
QUOTE 3
Defective product allegations
allegations
“They alleged that GranuFlo and NaturaLyte were defective and that Fresenius had engaged in deceptive and unfair trade practices in marketing and distributing the products.”
💡 Plaintiffs accused the company of knowingly misleading the market about product safety.
QUOTE 4
Financial injury to payors
economic
“MSP had been assigned the right to recover payments for financial injury suffered by Medicare Payers, first-tier, downstream, and related entities, as well as Medicaid payers.”
💡 Taxpayer-funded programs bore the cost of corporate negligence when private insurers paid for harm.
QUOTE 5
Claims would normally be untimely
delay_tactics
“MSP filed the present suit in September 2018, six years after their claims first accrued in 2012. In the normal course, this delay would have rendered the suit untimely under all relevant statutes of limitations.”
💡 Procedural barriers blocked injured parties from seeking accountability years after harm occurred.
QUOTE 6
No intent to certify class
delay_tactics
“He added that leadership counsel was nevertheless not planning on moving for certification, and that these cases were filed, for the most part, with respect to the issue of equitable tolling for the purposes of the limitations period.”
💡 Counsel admitted the class action was kept alive solely to extend deadlines, not to actively pursue relief.
QUOTE 7
Plaintiffs took no action for five years
delay_tactics
“Over the course of nearly five years, the Berzas plaintiffs took no action to move their claims forward, even as the entire MDL proceeding was assigned to a different district court judge.”
💡 Inaction allowed procedural defenses to mature while substantive safety questions went unanswered.
QUOTE 8
Court dismisses on timing, not merit
accountability
“The district court denied MSP’s bid for American Pipe tolling and granted defendants’ motion to dismiss.”
💡 The case was thrown out on procedural grounds without ever addressing whether Fresenius’s product caused harm.
QUOTE 9
American Pipe not a blank check
delay_tactics
“To allow such a gambit to substitute for pleading and actively pursuing a class action would run contrary to the aims of American Pipe, the watchwords of which are efficiency and economy of litigation.”
💡 The court rejected indefinite tolling but left substantive safety allegations unresolved.
QUOTE 10
Efficiency over accountability
accountability
“Neither efficiency nor economy is furthered by holding a request for certification on inactive life support simply to delay indefinitely the need to bring forward individual claims.”
💡 The opinion prioritized procedural efficiency over public health accountability.
QUOTE 11
Vulnerable patients at risk
health
“Dialysis recipients tend to be some of the most vulnerable people in our healthcare system, often with underlying conditions that make them highly susceptible to complications.”
💡 The patient population harmed by GranuFlo was especially fragile and dependent on trustworthy medical products.
QUOTE 12
Public relied on litigation, not regulation
regulatory
“The public relied on litigation after harm had already been done to unearth the truth.”
💡 Regulatory agencies failed to proactively protect patients, leaving courts as the only recourse after injury.
QUOTE 13
Corporate choice: safety or profit
profit
“If Fresenius had acted sooner by withdrawing or redesigning the product, or issuing clearer warnings, lives might have been saved, and financial losses spared.”
💡 The company allegedly chose market continuity over patient protection.
QUOTE 14
MSP’s burden unmet
accountability
“Ultimately, MSP bears the burden of establishing its entitlement to tolling under the doctrine of American Pipe. The evidence MSP presents to demonstrate that Berzas remained a class action even after the filing of the Master Complaint shows, at best, that there was no longer any intention to actually move for class certification.”
💡 The court placed burden of proof on injured parties, making accountability nearly impossible.
QUOTE 15
Complaint remains untimely
conclusion
“As such, MSP’s bid for continued American Pipe tolling beyond April of 2015 fails, and its complaint remains untimely.”
💡 Procedural technicalities defeated substantive claims of harm, leaving victims without legal remedy.
Frequently Asked Questions
What is GranuFlo and why is it controversial?
GranuFlo is an acid concentrate used in dialysis treatments. In March 2012, Fresenius issued a public warning that it could cause cardiopulmonary arrest in certain patients, triggering hundreds of wrongful death and injury lawsuits.
What did the lawsuits against Fresenius allege?
Plaintiffs alleged that GranuFlo and related product NaturaLyte were defective and that Fresenius engaged in deceptive and unfair trade practices. They claimed the company failed to adequately warn healthcare providers and patients in time.
Why was MSP Recovery’s lawsuit dismissed?
The First Circuit ruled that MSP Recovery filed its complaint too late. The court held that the statute of limitations stopped being tolled in 2014 or 2015 when the earlier Berzas class action plaintiffs abandoned their class allegations.
Did the court rule on whether GranuFlo actually caused harm?
No. The appellate court dismissed the case on procedural timing grounds without addressing the substance of the safety allegations or whether Fresenius’s product caused patient injuries.
What is American Pipe tolling?
American Pipe tolling is a legal doctrine that suspends the statute of limitations for potential class members while a class action is pending. This allows individuals to file their own lawsuits later if the class is not certified.
How did the Berzas class action factor into this case?
MSP Recovery argued it was a member of the Berzas putative class, which would have extended the filing deadline. The court disagreed, finding that Berzas plaintiffs effectively abandoned class claims by 2014 when they filed individual Short Form Complaints.
Who were the healthcare payors affected by this?
MSP Recovery represented Medicare, Medicaid, and other third-party payors who paid for medical treatments related to injuries allegedly caused by GranuFlo during dialysis.
What happened to the individual Berzas plaintiffs?
Five of the nine original Berzas plaintiffs filed Short Form Complaints in March 2014 identifying only themselves and their next of kin. The other four filed dismissals in June 2014. The case was finally closed in April 2019.
Were there other lawsuits about GranuFlo?
Yes. The court documents reference a stream of wrongful death and personal injury lawsuits consolidated into multidistrict litigation in Massachusetts, indicating widespread claims against Fresenius.
What can I do if I or a family member was harmed by a medical device?
Consult a qualified attorney as soon as possible. Statutes of limitations can bar claims filed too late. Document all medical records, treatments, and communications with healthcare providers and manufacturers.
💡 Explore Corporate Misconduct by Category
Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.
- 💀 Product Safety Violations — When companies risk lives for profit.
- 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
- 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
- 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
- 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.
